The specificities of markers ALDH1A1, CD271, CD133 and ISLR expression in endometrioid adenocarcinoma of the uterine corpus at different disease outcomes
https://doi.org/10.51523/2708-6011.2024-21-3-10
Abstract
Objective. To identify the expression patterns of ALDH1A1, CD133, CD271 and ISLR in endometrioid adenocarcinoma of the uterine corpus at different outcomes.
Materials and methods. Histological archival material of 188 cases of endometrioid adenocarcinoma of the uterine corpus were used in the study. All cases were divided into 2 groups according to the outcome of the disease. The group with favourable outcome included 148 cases without tumour progression. The group with unfavourable outcome included 40 patients who had disease progression during follow-up. ALDH1A1, CD271, CD133 and ISLR expression was evaluated as the percentage of positive cells to the total number of cells in the field of view. Comparison of groups was performed using the Mann-Whitney test.
Results. There were statistically significant differences between groups (p<0.05) in ALDH1A1, CD271, CD133 and ISLR expression. Conclusion. Expression of ALDH1A1, CD133 ISLR markers in groups with different disease outcome may indicate their predictive role in the prognosis of endometrioid adenocarcinoma of the uterine corpus. Keywords: endometrioid adenocarcinoma, ALDH1A1, CD271, CD133, ISLR> ˂ 0.05) in ALDH1A1, CD271, CD133 and ISLR expression.
Conclusion. Expression of ALDH1A1, CD133 ISLR markers in groups with different disease outcome may indicate their predictive role in the prognosis of endometrioid adenocarcinoma of the uterine corpus.
About the Authors
D. A. Zinovkin
Gomel State Medical University
Belarus
Belarus
Dmitry A. Zinovkin, Candidate of Biological Sciences, Associate Professor, Associate Professor at the Department of Pathology,
Gomel
R. V. Zyatikov
Gomel Regional Clinical Pathology Bureau
Roman V. Zyatikov, Pathologist at the General Pathology Department,
Gomel
J. I. Teterskaya
OMNIA Clinic (ltd)
Julia I. Teterskaya, Surgeon,
Gomel
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021 Feb 4;71(3):209-249. DOI: https://doi.org/10.3322/caac.21660
2. Watkins JC, Downing MJ, Crous-Bou M, Busch EL, Chen MM, De Vivo I, et al. Endometrial tumor classification by histomorphology and biomarkers in the nurses’ Health Study. Journal of Cancer Epidemiology. 2021 Mar 12;2021:1-9. DOI: https://doi.org/10.1155/2021/8884364
3. Xia Y, Wang S, Sun Y, Wang W, Chang S, Zhang Z, et al. FZD5 induces chemoresistance through ALDH1A1 in ovarian cancer. 2024 Jan 29; DOI: https://doi.org/10.21203/rs.3.rs-3875162/v1
4. DeLeo AB. Targeting cancer stem cells with ALDH1A1-based immunotherapy. OncoImmunology. 2012 May;1(3):385-387. DOI: https://doi.org/10.4161/onci.18826
5. Vidal A, Redmer T. Decoding the role of CD271 in melanoma. Cancers. 2020 Aug 31;12(9):2460. DOI: https://doi.org/10.3390/cancers12092460
6. Shen W. Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271. Cancer Biology & Medicine. 2019 Aug 1;16(3):498-513. DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0073
7. Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, Miyai Y, et al. Roles of the mesenchymal stromal/stem cell marker Meflin/ISLR in cancer fibrosis. Frontiers in Cell and Developmental Biology. 2021 Oct 5;9. DOI: https://doi.org/10.3389/fcell.2021.749924
8. Li S, Zhao W, Sun M. An analysis regarding the association between the ISLR gene and gastric carcinogenesis. Frontiers in Genetics. 2020 Jun 16;11. DOI: https://doi.org/10.3389/fgene.2020.00620
9. Yondem E, Pesen-Okvur D. Cancer cell-derived extracellular matrix promotes differentiation of fibroblasts into cancer-associated fibroblasts. BioRxiv. 2024 Apr 20. DOI: https://doi.org/10.1101/2024.04.15.589578
10. Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 2018 July 09. DOI: https://doi.org/10.1186/s40169-018-0198-1
Supplementary files
Review
For citations:
Zinovkin D.A., Zyatikov R.V., Teterskaya J.I. The specificities of markers ALDH1A1, CD271, CD133 and ISLR expression in endometrioid adenocarcinoma of the uterine corpus at different disease outcomes. Health and Ecology Issues. 2024;21(3):75-80. (In Russ.) https://doi.org/10.51523/2708-6011.2024-21-3-10
Views: 124
Email this article 